RESULTS	After crossover to 1 year of treatment with ranibizumab , average VA gains in the sham/0 .5 mg group were lower compared with gains seen in the ranibizumab patients after 1 year of treatment ( 2.8 vs. 10.6 and 11.1 letters ) .\